Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rare cancer study: does surgery help patients live longer?

NCT ID NCT07596654

Knowledge-focused Sponsor: yi shen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study looks at people with a rare and aggressive type of esophageal cancer that hasn't spread. It compares those who had surgery (with or without other treatments) to those who had non-surgical treatments like chemotherapy and radiation. The goal is to see which approach helps patients live longer and guide future treatment choices.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 4 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients pathologically diagnosed with limited-stage small cell esophageal carcinoma (LS-SCEC) who received treatment at Jinling Hospital during the study period will be retrospectively identified from institutional medical records. Eligible patients will include those who underwent surgical treatment (with or without neoadjuvant or adjuvant therapy) as well as those who received definitive non-surgical treatment, including chemoradiotherapy-based approaches. Clinical characteristics, treatment information, and follow-up data will be collected for survival analysis.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients pathologically diagnosed with primary small cell esophageal carcinoma (SCEC). * Patients classified as having limited-stage disease at initial diagnosis, defined as tumor confined to the esophagus and/or regional lymph nodes without evidence of distant metastasis. * Patients who received definitive treatment at the study institution, including surgical treatment (with or without neoadjuvant or adjuvant therapy) or definitive non-surgical treatment such as chemoradiotherapy-based therapy. * Patients with complete baseline clinicopathological and treatment information available in the medical records. * Patients with available follow-up and survival outcome data. Exclusion Criteria: * Patients with extensive-stage disease or distant metastasis at diagnosis. * Patients with mixed histological subtypes in which small cell carcinoma was not the predominant component. * Patients who received palliative treatment only. * Patients with a history of other active malignant tumors within the previous 5 years. * Patients with incomplete key clinical, treatment, or follow-up data. * Patients under 18 years old.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoma of esophagus Esophageal Neoplasms esophageal small cell neuroendocrine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal carcinoma Limited-stage small cell esophageal carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Jinling Hospital, Nanjing, Jiangsu Province, China.

    RECRUITING

    Nanjing, Jiangsu, 210002, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.